For the quarter ending 2026-03-31, TCRX made $982K in revenue. -$28,666K in net income. Net profit margin of -2919.14%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration and license revenue | 982 | 2,567 | 2,511 | 3,076 |
| Research and development | 21,904 | 20,039 | 31,689 | 32,634 |
| General and administrative | 8,217 | 6,386 | 7,874 | 9,095 |
| Total operating expenses | 30,121 | 26,425 | 39,563 | 41,729 |
| Loss from operations | -29,139 | -23,858 | -37,052 | -38,653 |
| Interest and other income, net | 1,162 | 1,583 | 2,041 | 2,390 |
| Interest expense | 689 | 702 | 699 | 689 |
| Total other income | 473 | 881 | 1,342 | 1,701 |
| Net loss | -28,666 | -22,977 | -35,710 | -36,952 |
| Unrealized loss on available-for-sale securities | 0 | -51 | - | - |
| Comprehensive loss | -28,666 | -23,028 | - | - |
| Basic EPS | -0.22 | -0.177 | -0.28 | -0.28 |
| Diluted EPS | -0.22 | -0.177 | -0.28 | -0.28 |
| Basic Average Shares | 129,913,376 | 129,864,699 | 129,835,938 | 129,730,451 |
| Diluted Average Shares | 129,913,376 | 129,864,699 | 129,835,938 | 129,730,451 |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)